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Abstract 
 
Background: Gastric cancer is commonly seen in the Western Cape. There are 
numerous factors that contribute to the development of this cancer and these include 
both environmental and genetic factors. Amongst the genetic factors, the E-cadherin 
(CDH1) gene is said to play a major role in the development of gastric cancer. Both 
germline and somatic mutations have been identified in the CDH1 gene. The germline 
mutations span the entire exon of this gene and are seen in approximately 29% to 56% 
of familial gastric cancers. On the other hand, CDH1 somatic mutations are seen in 
approximately 31% of sporadic cancers. These mutations have been identified in exons 
7 to 10, with exons 8 and 9 being the commonly mutated regions. 
Objective: The primary objective of this study was to determine the prevalence of 
CDH1 genetic mutations in gastric cancer in the Western Cape and to correlate these 
findings with the demographic/clinicopathologic data. 
Design: A total of 102 gastric cancer cases were collected from the archives of the 
Division of Anatomical Pathology, University of Cape Town/NHLS Groote Schuur. 
DNA was then extracted from FFPE tissues and verified by amplifying exon 2 of the 
insulin gene. Following the insulin PCR, exon 8 and 9 of the CDH1 gene were 
amplified. The PCR products were sequenced and the sequencing data was analysed 
using Bioinformatics tools (BioEdit and ClastalW). 
Results: Good quality DNA was obtained from 44 cases insulin PCR, however, only 26 
of the 44 samples were amplified for exon 8. CDH1 mutations were identified in only 2 
of the 26 (7.6%) cases for exon 8. Only 2 samples were amplified for exon 9, but the 
sequencing reaction was unsuccessful. The mutational data was correlated with 
clinicopathologic features; however no significant conclusions could be reached due to 
the low frequency of mutations in this study. 
Conclusion: This study showed that there was a low prevalence of CDH1 genetic 
mutations in our study cohort. 
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CHAPTER 1 
1. Introduction 
 
1.1. Carcinogenesis 
 
Carcinogenesis is an uncontrolled cell growth and survival of abnormal cells 
(Yamamoto et al 2011; Zhang et al., 2008), which consists of initiation, promotion and 
progression stages. The consequence is cell accumulation, loss of tissue differentiation, 
loss of cellular adhesion, nuclear enlargement, enhanced mitotic activity and eventually 
metastasis (Coup et al., 2004; O'Leary et al., 2011). Cancer cells can invade the blood 
vessels and metastasise to various organs in the body. Secondly, they can invade the 
lymphatic vessels and spread to the lymph nodes. Cancer cells are classified according 
to its appearance or shape on a cell surface. They could have a sessile, papillary, 
polypoid, fungating, ulcerated and/or annular appearance. Cancer is also distinguished 
in accordance with the type of cell or tissue it originates from, namely the epithelial and 
connective tissues. Epithelial malignant tumours are termed carcinomas whilst those of 
connective tissues are called sarcomas. 
 
Furthermore, epithelial tissues are either glandular or non-glandular. The non-glandular 
cancerous tumours are named using the epithelial cell type e.g. squamous and 
transitional cell carcinomas. Conversely, the glandular tumours are specified as 
adenocarcinomas and are accompanied by the type of tissue they arise from. Tumours 
also resemble the cells or tissue type from which they originate. This is termed tumour 
differentiation. They could be well, moderately or poorly differentiated (Hottenrott, 
2012). The well differentiated tumours almost resemble the tissues of their origination 
and are less aggressive. The poorly differentiated ones are totally different from their 
tissues of origination. The moderately differentiated malignancies lie in between the 
above two types. As a result, the poorly differentiated tumours are more difficult to 
diagnose than the well and moderately differentiated types. 
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Several factors play a significant role in the initiation, promotion and progression of 
cancer. These include deregulation of molecular pathways, genetic instabilities and 
environmental exposures (Cano, 2008).  One of the molecular pathways is the cell cycle 
which is a mechanism by which cells divide. It is divided into gap phase 0 (G0), gap 
phase 1 (G1), DNA synthesis (S), gap phase 2 (G2), and mitosis (M). This pathway is 
composed of proteins i.e. cyclins (G1/S cyclins, S cyclins, M cyclins, G1 cyclins) and 
cyclin-dependent kinases (CDK). These molecules form complexes and modulate the 
progression from one stage of the cell cycle to another (Vermeulen et al., 2003). 
Checkpoints are identified within the cell cycle stages to ensure that events such as 
DNA synthesis proceed accordingly. If there is any DNA damage, the checkpoints arrest 
the cell cycle until the problem is repaired (Collins et al., 1997). Alterations or 
disturbances in this cycle may therefore lead to cancer development. 
 
Molecules which regulate the G1/S phase such as proto-oncogenes and tumour 
suppressor genes may undergo alterations and hence contribute towards cancer 
formation. Additionally, checkpoints such as those responsible to check DNA damage 
and modulate DNA replication may be genetically compromised and then trigger the 
development of cancer (Bartek et al., 1999).  
 
Apoptosis, also known as programmed cell death is a mechanism required for 
embryonic growth and tissue homeostasis. It is activated in response to DNA damage 
and abnormal cell growth and development (Renehan et al., 2001). There are a number 
of genes that are involved in the regulation of apoptosis. The key genes include the 
tumour suppressor gene p53, anti-apoptotic gene bcl-2 and the pro-apoptotic gene bax 
(Sjostrom and Bergh, 2001). Furthermore, these genes may accumulate mutations and 
disrupt the apoptotic process, resulting to tumour initiation, progression and metastasis 
(Lowe and Lin, 2000; Carnero, 2002). 
 
The majority of human malignancies develop due to genetic instabilities (Langauer et 
al., 1998). These genetic instabilities involve DNA damage and repair (Diaz, 2008). 
DNA may be damaged as a result of a number of abnormalities such as alterations in the 
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gene and chromosome number. Additionally, DNA may also be impaired due to 
radiation, namely, X-rays or gamma-rays. This results in DNA double strand breaks 
(DSBs) which in turn leads to chromosomal abnormalities (Okayasu, 2011). 
Chromosome translocation is another aberration that occurs due to DNA damage 
(Langauer et al., 1998). These DNA abnormalities may create mutations that promote 
carcinogenesis (Finn et al., 2012).  
 
DNA repair is a mechanism that corrects errors such as repeat sequences, mismatches 
and strand breaks which may occur during DNA replication (Madhusudan and 
Middleton, 2005). The two important repair mechanisms are the nucleotide excision 
(NER) and (MMR) mismatch repair (Langauer et al., 1998). The NER system serves to 
eradicate the DNA damaged as a result of ultraviolet light. On the other hand, during 
DNA synthesis the MMR gets rid of mismatched bases or DNA loops that arise as a 
result of DNA slippage at microsatellites (Leibeling et al., 2006). When DNA repair 
genes accumulate mutations it gives rise to the development of cancer through this 
mechanism (Hoeijmakers, 2001).  
 
1.2. Tumour suppressor genes 
 
Tumour suppressor genes (TSGs) are a group of molecules which are involved in the 
modulation of biological processes such as cell proliferation, cell death and cell 
invasion. They can lead to the formation and progression of cancer when their function 
is lost (Weinberg, 1989; Macleod, 2000; Lai et al., 2012). Their inactivation involves a 
mechanism called the Knudson “two” hit hypothesis.  Therefore, for tumour suppressor 
genes to give rise to cancer, two hits are required to totally deactivate both gene copies. 
Moreover, these genes are known to cause hereditary type of cancers (Collins et al., 
1997).  
The most important TSGs recognized in human cancers include the p53, retinoblastoma 
(Rb), APC, WT1 and NF1. However, the most common gene involved in more than half 
of the cancers is the p53 gene (Hussain and Harris, 1998). Other TSGs include PTEN, 
BRCA1 and the E-cadherin gene (Christofori and Semb, 1999; Lai et al., 2012).  
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1.3. Oncogenes 
 
Proto-oncogenes play an important role in cellular growth and proliferation. When 
activated, they act as oncogenes and therefore promote tumour formation and 
progression (Lehman et al., 1991). Only a single gene copy of the gene needs to be 
mutated in order to give rise to cancer, therefore the Knudson “two” hit hypothesis does 
not apply in this regard (Grander, 1998). A number of proto-oncogenes such as; TRK, 
MET, RET, and KIT have been identified in cancer formation (Sanchez-Carbayo and 
Cordon-Cardo, 2002). Other genes include the c-MYC, ABL, RAS, MYB, ERBA, ERBB2, 
MYCN and MYCL gene (Schwab, 1998). 
  
1.4. Environmental exposures and carcinogenesis 
 
There are various environmental factors that impact on carcinogenesis. These include; 
infections, lifestyle and chemical exposures. Pathogenic infections have been identified 
as a cause of malignant tumours. These include bacterial, viral and fungal infections 
(Correa, 2003). Some of the viral pathogens involved in carcinogenesis include the 
Epstein-Barr Virus (EBV), Human papillomavirus (HPV), Human herpes virus (HHV) 
and Hepatitis C virus (Stockfleth et al., 2004; Mclaughlin-Drubin and Munger, 2008; 
Hino et al., 2009). Bacterial pathogens such as Helicobacter pylori, Mycoplasma, 
Chlamydia pneumonia, Haemophilus influenza and Staphylococcus strains have also 
been implicated in carcinogenesis (Apostolou et al., 2011; Vogelmann and Amieva, 
2007). Lifestyle factors include diet, smoking and alcohol consumption. Various 
chemicals have also been implicated as a causative agent for cancer development. These 
include; gasoline, glass, wool, ethylene oxide and radon gas (Huff, 1993).  
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2. Background Review 
 
2.1. Anatomy of the stomach 
 
The stomach is located in the upper compartment of the abdominal cavity. This organ 
lies beneath the diaphragm and liver and is sub-divided into four parts, namely the 
cardia, fundus, body and the pylorus. The pylorus is further partitioned into three areas 
including the pyloric antrum, pyloric canal and pylorus (Tortora and Derrickson, 2011). 
The stomach has two curvatures, namely the lesser and the greater curvatures. The right 
superior part of the stomach wall forms the lesser curvature, whereas the greater 
curvature is formed by the left inferior portion (Tortora and Derrickson, 2011). 
 
There are sphincters that control the passage of food into and out of the stomach. The 
lower oesophageal or cardiac sphincter modulates the opening of the oesophagus into 
the stomach. The pyloric sphincter on the other hand, regulates the opening from the 
pyloric part into the first part of the duodenum (Tortora and Derrickson, 2011).   
 
2.2. Histology of the stomach 
 
The stomach wall has four layers: the mucosa which lies on the surface, submucosa, 
muscularis externa and serosa. The mucosa is composed of surface mucus secreting 
simple columnar epithelial cells also referred to as mucous cells. Furthermore, the 
mucosa consists of an areolar connective tissue called the lamina propria. The mucosa is 
separated from the submucosa by a smooth muscle layer called muscularis mucosae 
(Tortora and Derrickson, 2011). The gastric glands are located within the mucosa which 
extends down into narrow paths called gastric pits. These glands consist of three cell 
types depending on where they are located in the stomach. These are the mucous neck 
cells, chief cells and parietal cells. The submucosa of the stomach consists of areolar 
connective tissue. Within the muscularis externa layer, there are three layers of the 
smooth muscle: an outer longitudinal layer, middle circular layer and an inner oblique 
layer. 
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Figure 1:  The H&E staining of the stomach walls, mucosa, submucosa and muscle 
layer. 
 
3. Gastric Cancer 
 
Gastric carcinoma is described as a malignant tumour that develops from the epithelial 
tissue of the stomach (Forx and Wang, 2007). This malignancy is histologically 
classified into two forms, namely the diffuse and intestinal types according to the 
Lauren Classification system (Hackenson et al., 2010). 
 
The intestinal type developing from epithelial cells of the mucosa typically forms 
glands (Yamamoto et al., 2011). It is more prevalent in high risk areas and occurs most 
frequently in older people. It occurs primarily in males and is characterized by a slow 
growth, and is often highly differentiated (Corso et al., 2012). Further, it involves the 
distal stomach and proceeds from normal mucosa through atrophic gastritis, intestinal 
metaplasia, dysplasia and eventually progressing to cancer (Kudo et al., 2011). These 
cancer cells usually demonstrate cell adhesive properties and may resemble either a 
sheet like or nested structure (Padmavathy et al., 2011). 
 
 
 
Mucosa 
Submucosa 
Muscle layer 
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 The diffuse type on the other hand has an early age of onset and commonly occurs in 
low risk areas (Hackenson et al., 2010; Chen et al., 2011; Corso et al., 2012). It occurs 
in younger people, commonly females, and is characterized by enlarged dispersed cells 
which have abundant cytoplasm and prominent nucleoli (Correa and Piazuelo, 2011). 
This type of gastric cancer invades the abdominal wall, and proximal stomach, 
especially the cardia. Symptomatic individuals present with abdominal symptoms such 
as epigastric pain, early satiety and weight loss (Chen et al., 2011; Foster et al., 2011). 
Additionally, it may present as signet ring adenocarcinoma, usually together with lymph 
node involvement and distant metastasis (Chen et al., 2011).  
 
3.1. Worldwide Prevalence of gastric cancer 
 
Gastric cancer is rated as the fourth most frequent malignancy in the world with 
988,000 cases per annum. It is the second leading cause of cancer mortality with 
736,000 deaths per year, worldwide. The global estimated new cases and deaths 
amongst men and women are (640,000 cases and 463,000 deaths); and (384,000 cases 
and 273,000 deaths), respectively. Incidence and death rates, however, differ greatly 
amongst various populations. Stomach cancer is less frequent in more developed 
regions such as Europe, Australia, New Zealand and North America with 274, 000 cases 
and 180,000 deaths per annum. High incident regions include developing areas; Africa, 
Eastern Asia and South America with 713,000 cases and 555,000 deaths per year 
(Globacan, 2008). 
 
The highest incidence rates (713,000) are seen in developing countries with 467,000 
cases and 353,000 deaths in men, whilst in women, there are 246,000 cases and 202,000 
deaths. On the other hand, prevalence and mortality rates are low in developed countries 
(173,000 cases and 110,000 deaths in men; 101,000 cases and 70,000 deaths in women). 
In general, in countries like China there are 463,000 cases and 352,000 deaths; central 
and eastern Europe (165,000 cases and 133,000 deaths) and Western Pacific regions 
(621,000 cases and 432,000 deaths). Further, Canada and Korea have increased 
incidence and death rates per year (Globacan, 2008). 
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4. The risk factors of Gastric Cancer 
 
There are several factors that contribute to the development of gastric adenocarcinoma 
and these include environmental, genetic and epigenetic agents. Environmental factors 
include Helicobacter pylori (H. pylori) infection, diet, smoking and alcohol 
consumption. Diet and H. pylori infection are the major contributing factors.  
 
4.1 Helicobacter pylori 
4.1.1. Helicobacter pylori (H. pylori) Morphology 
 
H. pylori is a microaerophilic gram negative bacterium with a length of 2 to 4 µm and a 
width of 0.5 to 1 µm (Serrano et al., 2007). This bacterium is spiral in shape but can 
also resemble a rod (Kim et al., 2011). The outer membrane possesses 2 to 6 sheathed 
unipolar flagella with a length of about 3 µm, which allow motility (Correa and 
Piazuelo, 2011) especially in a mucus environment of the stomach (Kusters et al., 2006). 
H. pylori also has virulence factors which contribute to the pathogenesis of 
gastroduodenal disease such as peptic ulcers, atrophic gastritis and gastric cancer 
(Matsunari et al., 2012). These factors include the Cag pathogenecity island (PAI); 
CagA protein, vacuolating toxin (VacA); blood group antigen binding adhesin (BabA) 
and the (dupA) duodenal ulcer producing gene (Wen and Moss, 2009). 
 
4.1.2. H. pylori Colonization Mechanism and Gastric cancer 
 
H. pylori was categorized by the World Health Organization (WHO) as a class I 
carcinogen due to its significant role in the pathogenesis of gastric adenocarcinoma 
(Kandulski and Malfertheiner, 2008). This bacterium has been predicted to infect 
approximately half of the population, globally (Bartchewsky et al., 2009). It is 
transported through fecal and oral contamination amongst families during childhood 
(Ruggiero, 2012). The H. pylori bacterium surface receptors, namely, BabA attaches or 
binds to the fucosylated Lewis B-binding (Leb-binding) antigen on the mucosa or 
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epithelial tissue of the stomach (Stoicov et al., 2004; Forx and Wang, 2007).  
 
Once it binds to the epithelium, the virulent factors namely; CagA and VacA colonise 
the gastric mucosa (Correa and Piazuelo, 2011). This is followed by the release of a 
urease enzyme which catalyses urea and then produces ammonia and carbon dioxide 
(Stingl et al., 2002). The ammonia creates an alkaline environment which allows the 
bacterium to thrive in the acidic stomach. The ammonium compound also helps the H. 
pylori to persistently colonize the cell surface of the gastric mucosa and initiate disease 
(Burne and Chen, 2000). 
 
The bacterium persistently infiltrates gastric mucosa and induces a chronic 
inflammation. The gastric mucosa becomes wounded as a result of the inflammation, 
thereby reducing gastric glands and causing atrophy. A different type of epithelial tissue 
called the intestinal metaplasia (IM) is then regenerat d by the damaged mucosa (Kudo 
et al., 2011). An atrophic gastritis together with IM is followed by dysplasia and 
eventually leads to the intestinal type of gastric cancer.  Diffuse gastric cancer on the 
other hand develops from atrophic gastritis in the absence of IM (Kim et al., 2010). 
 
4.1.3. H. pylori infection in gastric mucosa - associated lymphoid tissue (MALT) lymphoma 
 
Gastric lymphoma develops in the stomach as a result of chronic gastritis induced by 
the H. pylori bacterium. Gastric lymphoma is categorised as the MALT, diffuse large B 
cell and T cell lymphoma which is not commonly seen in the stomach. The MALT 
lymphoma is specified as the low or high grade lymphoma. The low grade lymphoma is 
treated by eradicating the H. pylori bacterium as opposed to the high grade lymphoma, 
which is treated by chemotherapy. The genetic host factors of the H. pylori bacterium 
may play a significant role in the pathogenesis of this lymphoma. This bacterium has 
been identified in approximately 98% patients with gastric MALT lymphoma. However, 
only a small percentage of people with H. pylori infection develop gastric MALT 
lymphoma (Witkowska and Smolewski, 2013). 
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4.1.4. Intestinal metaplasia (IM) and gastric cancer 
 
Intestinal metaplasia is regarded as a precancerous lesion of gastric cancer. This 
condition develops from gastric stem cells forming epithelial cells (absorptive cells, 
goblet cells and Paneth cells), (Erkan et al., 2012). There are three categories of IM: 
types I, II and III (Eriksson et al., 2008). The type I IM has a low pathogenic effect on 
stomach cancer and can also be called complete IM (Leung and Sung, 2002). Further, 
the type I IM histologically resembles the mucosa of the small intestine and is 
characterized by goblet cells which produce sialomucins, Paneth and absorptive cells 
that are positioned below the brush border (Li et al., 2010). 
 
On the other hand, type II and III IM increase the degree of malignancy and can also be 
referred to as the incomplete IM. Incomplete IM is histologically distinguished by 
different sizes of multiple mucus vacuoles and the absence of a brush border (Garay et 
al., 2004). In addition, this IM exhibits goblet cells which produce sulfomucins, 
however, it must be noted that Paneth cells are absent (Kang et al., 2011). 
 
4.1.5. Helicobacter pylori infection in Gastric Cancer 
 
The incidence of H. pylori infection has been investigated amongst patients with gastric 
adenocarcinoma in a number of studies (Watabe et al., 2005; Nam et al., 2011; 
Tsukanov et al., 2011). The infection has been identified in both diffuse and intestinal 
histological types and seen in non cardia gastric cancer (Lamb and Chen 2012). This 
infection plays a very important role in the progression of gastric cancer and promotes 
invasion and metastasis of the cancer (Parsonnet et al., Qiu et al., 2010; 1991; Kang et 
al., 2011). However, the eradication of H.pylori reduces the risk of developing stomach 
cancer. In a study that was carried out in different populations, H.pylori infection was 
eradicated and this was accompanied by a risk reduction rate of gastric cancer (10% in 
rural areas and 6% in urban locations) (Yeh et al., 2009). 
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4.2. Diet and its role in Gastric Cancer 
 
Foods and beverages containing carcinogenic chemicals such as N-nitroso compounds 
and aromatic amines play a crucial role in tumour growth. These compounds induce 
alkylation and cause DNA damage (Lijinsky, 1999). Additionally, low or poor ingestion 
of fruit and vegetables and a high intake of salty foods increase the risk of gastric 
carcinogenesis. The method of food preservation and storage plays an important role in 
cancer development. Food smoking, as a method of preservation and less refrigeration 
is an important contributing factor (Yalcin, 2009). The use of refrigerators decreases the 
production of nitroso compounds and also sustains antioxidants in food (Park et al., 
2011). Additionally, the use of salt when preserving food contributes towards gastric 
carcinogenesis by degrading the mucosal layer and causing inflammation in the stomach 
(Tsugane and Sasazuki, 2007). Nutrient deficiencies of folate, betanine, choline, zinc, 
vitamin C, selenium, vitamin B6 and vitamin B12 can also contribute towards gastric 
carcinogenesis (Su, 2012).  
 
Numerous studies have reported the correlation between diet and gastric cancer (Ngoan 
et al., 2002; Kelley and Duggan, 2003; De Stafani et al., 2004; Nan et al., 2005). It was 
shown that pickled, salted and fatty foods significantly enhanced the risk of cancer 
development. This study involved 116 patients and also showed that high intake of fruit 
and vegetables on the other hand decreased the risk of stomach cancer (Ngoan et al., 
2002). Another study with 240 subjects also discovered that a high consumption of 
starchy foods such as rice; white bread; potatoes and tubers played a significant role in 
the development of this cancer. Further, it was also concluded that diets high in 
vegetables and fruits reduced the risk of developing stomach cancer (De Stafani et al., 
2004). 
 
Malnutrition is an important contributing factor to the development of gastric cancer. An 
association between malnutrition and the risk of stomach cancer was investigated in 100 
gastric cancer patients. This study showed a significant association between 
malnourished individuals and risk of gastric cancer (Gavazzi et al., (2011). Another 
dietary factor contributing towards the development of stomach cancer is heme iron. A 
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study carried out in 444 individuals to investigate the impact of heme iron showed that 
there was a 70% greater chance of developing stomach cancer in individuals with an 
increased heme iron in their diet (Jakszyn et al., 2011). 
 
4.3. Smoking and alcohol intake in gastric cancer 
 
Alcohol intake and cigarette smoking have also been implicated in the development of 
stomach cancer. The impact of cigarette smoking in gastric carcinogenesis was 
determined in a population study consisting of African Americans, Japanese Americans, 
Latino Americans, Native Hawaiians and Whites. Amongst these different populations, 
cigarette smoking increased the risk of developing this cancer in 98% of men and 78% 
of women (Nomura et al., 2012). In another study consisting of 391 cases, 68.79% 
heavy smokers were investigated and had about 59% increased risk of stomach cancer 
(Moy et al., 2010).  
 
In addition, alcohol may cause abnormalities during DNA synthesis and repair and thus 
contribute to the development of this tumour (Zhang et al., 2007). A study cohort 
consisting of 444 cases showed that an alcohol consumption of greater than 60 grams 
per day was highly associated with developing gastric tumour. On the other hand, 
individuals who consumed less than 60 grams per day had a low risk of developing the 
cancer (Duell et al., 2011). Heavy alcohol consumers had an approximately 50% 
increased risk of developing the stomach cancer than individuals who consumed less 
(Moy et al., 2010).  
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5. Epigenetic and Genetic factors 
5.1. Epigenetic factors 
 
Epigenetic factors modulate gene expression and function and do not influence the 
DNA coding gene sequences. They include DNA methylation and histone modification 
(Su, 2012). Approximately 90% of epigenetic changes are responsible for the 
development of cancer (Compare et al., 2011).   
 
5.1.1. DNA methylation 
 
DNA methylation is the addition of methyl groups to the promoter region of a gene. The 
methyl groups are added at the 5’-carbon position by enzymes called DNA 
methyltranferases (DNMTs) and form 5-methyl-cytosine (Zhao and Bu, 2005). These 
enzymes; DNMT3A, DNMT3B and DNMT1 initiate and maintain methylation (Tomita 
et al., 2010). The function conducted by these enzymes is vital for embryonic 
development (Williams, et al., 2011). DNMT3A and DNMT3B initiate methylation, 
while DNMT1 maintains it (Das and Singal, 2004). Genes can either be 
hypermethylated in the CpG dinucleotides e.g. tumour suppressor genes or 
hypomethylated e.g. oncogenes (Dumitrescu, 2012).  
 
The CpG dinucleotides are, in most cases unmethylated in normal cells (Jones and 
Baylin, 2002). It is when malignancy is present that methylation is observed. Gastric 
carcinoma is one of the malignant tumours where the CpG island is commonly 
methylated (Kang et al., 2003). The methylation status of some suppressor genes 
namely; E-cadherin (CDH1), APC, COX-2, DAP-kinase, GSTP1, hMLH1, MGMT, p16, 
p14, RASSF1A, THBS1 and TIMP3 was investigated in gastric cancer (Kang et al., 
2003). The CDH1 was one of the frequently methylated genes in 60.1% of the gastric 
cancer tissue samples (Kang et al., 2003).    
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5.2. Genetic factors  
 
Genetic instabilities namely; germline and somatic mutations, microsatellite instability 
and polymorphisms contribute to the risk of malignant formation. These instabilities are 
commonly identified in certain genes in patients with stomach cancer (Horri et al., 
1992; Richards et al., 1999; Yamada et al., 2011).  
 
6. Cadherin Molecules 
 
Cadherin molecules are a large family of transmembrane proteins that regulate cell-cell 
attachment during development. They depend on calcium ions for their function and are 
composed of at least three major subfamilies, namely classical cadherins, desmosomal 
cadherins and protocadherins, (Van Roy and Berx 2008). These calcium ions give the 
molecules a rigid structure and therefore protect them from proteolysis (Pokutta and 
Weis 2007). The name “cadherin” is used to classify cell-cell adhesion molecules in 
different tissues e.g. E- (Epithelial) cadherins, N- (Neural) cadherins, P-(Placental ) 
cadherins (Van  Roy and Berx 2008). All the cadherin proteins are composed of 
multiple extracellular cadherin repeats (EC), a single transmembrane and cytoplasmic 
region. These domains interact with the cytoskeleton and are therefore responsible for 
the cell adhesion of cadherin molecules (Nollet et al., 2000).  
 
6.1. E-cadherin protein structure and function 
 
The E-cadherin protein (Figure 2) plays a significant role in maintaining cell 
differentiation and normal architecture of epithelial tissues (Shore and Nelson, 1991; 
Suriano et al., 2003). It belongs to the family of classical cadherin molecules and 
consists of three domains i.e. 5 large extracellular repeats (EC1 to EC5) where the N-
terminal region is situated. Further, it also consists of an intracellular or transmembrane 
and a cytoplasmic domain (Graziano et al., 2003).  
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The C-terminal region is located in the cytoplasmic domain which adheres to the 
cytoskeleton through β, α and γ-catenins (Yamamoto et al., 2011). Additionally, this 
molecule consists of a juxtamembrane domain where the p120-catenin binds, preventing 
this molecule from degradation (Nollet et al., 2000). This transmembrane glycoprotein 
is involved in a cell signalling pathway namely, the Wnt signalling pathway and has 
been implicated in the development of certain tumours (Berx et al., 1995).    
 
 
Figure 2: A diagrammatic representation of the E-cadherin protein structure showing the 
different domains: extracellular (A), transmembrane (B) and cytoplasmic (C) domains. 
The diagram was amended from Mateus et al., 2009. 
 
7. The Wnt signalling pathway 
 
The Wnt signalling is a cellular pathway that consists of 19 Wnt genes (Wnt1, Wnt2, 
Wnt2B, Wnt 3, Wnt 3A, Wnt4, Wnt 5A, Wnt 5B, Wnt6, Wnt7A, Wnt7B, Wnt 8A, Wnt 
8B, Wnt 9A, Wnt 9B, Wnt 10A, Wnt 10B, Wnt 11 and Wnt16) in the human genome. It 
plays an important role in embryonic development (Kawakami et al., 2013; Zha et al., 
2012). The first genes that were discovered in this signalling were the int1 
(intergration1) from mouse tumour cells and its homologous gene, the Wingless gene 
from Drosophila melanogaster (Klaus and Birchmeier 2008). The Wnt signalling 
pathway is activated via two pathways namely, the canonical or Wnt/β-catenin and non-
canonical pathways. The canonical pathway consists of glycoprotein signalling 
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molecules such as ß-catenin, frizzled, APC, axin, GSK-3ß, TCF, c-MYC, Cyclin D1 
and MMP-7 (Duacas et al., 2005). 
 
7.1. β-catenin protein 
 
This 92 kDa molecule is encoded by the CTNNB1 oncogene and consists of 781 amino 
acids (Van Aken et al., 2001; Micu et al., 2010). It consists of a N-terminal region of 
about 150 amino acids, a C-terminal region with 100 residues and a central domain with 
12 armadillo (arm) repeats. These regions are where the E-cadherin and catenins bind to 
form the E-cadherin-catenin complex. This complex enhances cell-cell adhesion. 
(Pokutta and Weis 2007).  
 
7.2. Canonical or Wnt/β-catenin signalling pathway 
 
The canonical pathway (Figure 3) is also referred to as the Wnt/ß-catenin pathway and 
plays a crucial role in the pathogenesis of cancer (Akaboshi et al., 2009). It is activated 
when the Wnt ligands bind to frizzled (Fz) and lipoprotein-related (LRP 5 & 6) 
receptors in the plasma membrane. This binding leads to the phosphorylation of a 
dishevelled protein (Polakis, 2000). The dishevelled protein then deactivates the 
destruction complex (Axin-GSK3β-APC complex) that is responsible for degrading ß-
catenin. Since the destruction complex is deactivated, the ß-catenin protein becomes 
abundant in the cytoplasm and then translocates to the nucleus (Aberle et al., 1997). It 
then binds to T-cell factors (TCFs) and lymphoid enhancer factor (LEF) molecules 
(Korswagen, 2002).  
 
After adhering to TCFs, it regulates transcription of its target molecules namely, Cyclin 
D1, matrix metalloproteinase-7 (MMP-7), immunoglobulin transcription factor 2 (ITF-
2) and c-Myc (Doucas et al., 2005). These molecules then modulate the proliferation 
and differentiation of cells (Sugimura and Li, 2010). Further, this pathway also involves 
the interaction of the E-cadherin with catenin molecules such as beta (β), alpha (α) and 
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gamma (γ) catenins. The α-catenin which is also known as plaglobin, in turn interacts 
with the cytoskeleton for cell-cell adhesion (Van Aken et al., 2001). This complex 
forms a significant part of adherence junctions and regulates cell-cell adhesion. When 
the adhesive function of this complex is compromised, cells lose adherence to one 
another. This therefore allows reduced cell differentiation which is followed by the 
invasion and metastasis of tumour cells (Oliveira et al., 2009).   
 
In the absence of Wnt ligands, the molecules (Axin-GSK3β-APC) within the 
destruction complex phosphorylate ß-catenin protein, marking it for degradation 
(Korswagen, 2002). The ß-catenin molecule then becomes degraded by an E3 ubiqutin 
ligase, β-TrCP, inhibiting the transcription of Cyclin D1, MMP-7, ITF-2 and C-myc 
molecules (Kawakami et al., 2012).  
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
18 
 
 
Figure 3: A diagrammatic representation of the Wnt signalling pathway. In the absence 
of the Wnt ligand, β-catenin binds the destruction complex (APC/Axin/GSK3), and then 
becomes phosphorylated and degraded. In the presence of the Wnt ligand, the 
destruction complex then becomes deactivated and permits the translocation of β-
catenin to the nucleus (Catriona and Nusse, 2004). 
 
7.3. The canonical signalling pathway and gastric cancer 
 
This pathway contributes to gastric carcinogenesis. The abnormal expression of β-
catenin protein has been reported to increase the development of gastric cancer (Li et 
al., 2008). Further, this protein is seen in the cell membrane in normal gastric mucosa, 
while positioned in the nucleus in gastric cancer (Clements et al., 2002). Also, the 
changes encountered in the E-cadherin-β-catenin complex plays a crucial role in the 
development of stomach cancer. A study by Joo et al., (2001) investigated the 
expression of the four adhesion molecules (E-cadherin, β, α, and γ-catenins) in early and 
advanced gastric cancer patients and found an abnormal expression of the proteins 
investigated in diffuse gastric cancer individuals (Joo et al., 2001).  
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Another study assessed the expression of the aforementioned adhesion proteins in 91 
advanced gastric cancers. This study showed a reduced expression of β-catenin 
associated with site and depth of tumour invasion. Additionally, the E-cadherin and β-
catenin aberrant expression was seen in patients with metastasis to the lymph nodes 
(Czyzewska et al., 2010). In 2004, it was shown among 60 patients that accumulation of 
β-catenin to the cytoplasm and nucleus increases the risk of gastric adenocarcinoma. 
This protein was also localized in the cytoplasm and nucleus in 41.7% and 48.3% 
patients, respectively (Song et al., 2004).  
Chan and colleagues assessed the expression of the three proteins (E-cadherin, β-catenin 
and α-catenin) in 40 patients. Of these cases, 30% had a decreased expression of the 
three molecules. This study showed that the reduced expression of the E-cadherin-
catenin complex enhanced the risk of gastric adenocarcinoma (Chan et al., 2003). It was 
also determined in another research that E-cadherin, α-catenin and β-catenin was 
aberrantly expressed in 82%, 85% and 88% of 65 gastric carcinomas, respectively. The 
abnormal expression of the proteins was associated with the depth of invasion of the 
tumours (Guzman et al., 2006). In another study, the abnormal expression of these 
molecules (E-cadherin, α-catenin, β-catenin and γ-catenin) was associated with 
clinicopathologic features amongst 65 patients. The abnormal expression of the four 
proteins was seen in 24.6% and was associated with poorly differentiated and diffuse 
type of tumours (Joo et al., 2000). 
 
7.4. The Non-canonical pathway 
 
The non-canonical pathway is also known as the planar cell polarity and or Wnt Ca2+ 
pathway (Tada et al., 2002). This pathway plays a pivotal role in development and 
homeostasis. It is involved in the migration of neural crest cells during development (De 
Calisto et al., 2005). Further, it preserves stem cells in adults and is activated via two 
pathways i.e. the protein kinase C (PKC) and Jun-N terminal (JNK). The PKC pathway 
is activated when calcium is released and when Wnt ligands adhere to Frizzled receptors 
(Yamanaka et al., 2002). On the other hand, the JNK pathway is triggered when the 
dishevelled and Wnt proteins (5a, Wnt 5 and Wnt 11) bind to Frizzled molecules (Oishi 
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et al., 2003). The JNK molecule thus moves to the nucleus and modulates the 
transcription of several proteins (Doucas et al., 2005).  
 
This signalling pathway is also implicated in cancer development, particularly gastric 
malignancy, where it promotes the progression of cancer (Gencer et al., 2010). There 
are approximately 30% cases of gastric cancers which result from the dysfunction of the 
non-canonical signalling pathway (Sugimura and Li, 2010). 
8. The CDH1 gene structure 
 
The tumour suppressor gene, CDH1 is located on chromosome 16q22.1 (Figure 4) and has 2.6 
kilobases (kb) of coding sequences and contains 16 exons. This gene encodes a 120kDa 
epithelial cadherin (E-cadherin) protein (Pinho et al., 2011). The gene is commonly mutated, 
resulting in its loss of function and therefore give rise to malignancy.  
 
 
 
 
 
 
 
Figure 4: Diagrammatic representation of the E-cadherin gene location on the long arm 
of chromosome 16 at region 2, band 2 and sub-band 1 (16q22.1) 
(http://ghr.nlm.nih.gov/gene=CDH1). 
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8.1. The CDH1 gene and Familial Gastic Cancer 
 
Germline mutations are commonly identified in the CDH1 gene amongst individuals 
with familial gastric cancer (Suriano et al., 2003; Brooks-Wilson et al., 2004; Bacani et 
al., 2006; More et al., 2007; Lynch et al., 2011). These alterations span the entire coding 
sequence of this gene and are prevalent in approximately 29% to 56% of hereditary 
diffuse gastric cancer (HDGC) families (Lynch et al., 2005; Bacani et al., 2006; Corso et 
al., 2012).  
 
Bacani et al. (2006) identified 20 mutations in different regions of the gene, of which 12 
were novel. One of these mutations included a new nucleotide deletion (nt41delT) in 
exon 1. This variant resulted in reduced membrane expression of the E-cadherin protein 
leading to loss of function. Other mutants were also identified and localized in the 
5'UTR region (-117G>A; -71C>G). Alterations observed in the intronic segments were; 
48(+15)C>G; 387(+26)C>T, 2295(+53)G>A, 2439(+31)G>A and 48(+15)C>G. 
Interestingly, the majority of mutations observed were located in exons 3, 6, 7, 8 and 15 
were silent (Bacani et al., 2006).    
 
In another study, two missense germline mutations were identified by Suriano et al., 
(2003) with one having a negative impact on the E-cadherin protein structure and 
function. The specific mutations occurred in codons 617 (1849 G>A) and 634 (1901 
C>T). These produced the following amino acid substitutions; Ala to Thr and Ala to Val, 
respectively. The mutation in codon 617 was identified in the 5th extracellular domain, 
compromising the calcium binding site which impaired cell attachment, thereby 
promoting cell invasion (Suriano et al., 2003). 
 
Brooks-Wilson et al., (2004), identified a splice site mutation G>A at positions (+1) 
IVS5 and (+5) IVS 11, which was thought to be the cause of an in-frame deletion of 
exon 5 at position (+1) IVS5. The entire exon 8 was deleted while only a part of exon 11 
was deleted at position (+5) IVS11. Other alterations included, deletions in exons 3 
(382delC), 8 (1134del8), 9 (1212delC), 10 (1476delAG), 13 (2061delTG) and 15 
(2319delC). Other alterations included the following insertions 1134ins5, 1064insT and 
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1779insC in both exons 8 and 12. Furthermore, amino acid substitutions namely; 
A298T, W409R and R732Q were also identified. In addition, missense mutations 
identified included G892A, T1226T and G2195A in exons 7, 9 and 14, respectively. 
Significantly, all these genetic alterations disrupted the cell-cell adhesion and tumour 
suppressive role of the protein (Brooks-Wilson et al., 2004).  
 
A similar study conducted by More et al. (2007), detected 7 novel mutations and 2 that 
were previously identified in 9 of 36 HDGC families. The mutations were as follows; 
3(53C>G); 6 (715G>A) and 12 (1901C>T). These mutations resulted in the following 
amino acid substitutions; (p.Thr118>Arg; Gly239Arg and Ala634Val). Interestingly, the 
p.Thr118>Arg mutant generated a protein with an impaired adhesive function. 
Additionally, other mutations were also observed in intron 1 (49-2A>C); exon 8 
(1137G>A) and exon 15 (2440-6C>G). Furthermore, base pair deletions (1bp 
c.1107delC and 2bp c.1391_1392delTC) which resulted in the production of stop 
codons Asn369LysfsX392; Leu472HisfxX481 and Gln699X were also detected. These 
deletions resulted in truncation of the extracellular domains and therefore increased the 
risk of developing the tumour (More et al., 2007).   
 
Kaurah et al., (2007), discovered 13 mutations in 15 of 38 HDGC families. Six of these 
mutations were novel and were as follows; 1682-1683insA; 1913G>A; 2164+5G>A; 
2245C>T; 2343A>T and 2398delC. The mutations that were previously identified 
included; 715G>A; 283C>T; 1137G>A; 1397-1398delTC; 1901C>T; 2064-2065delTG 
and 2195G>A. Two novel missense mutations namely; 2245C>T and 2343A>T were 
found to compromise cell-cell adhesion (Kaurah et al., 2007). The majority of these 
mutations resulted in a truncated protein which impaired the cell adhesion function 
(Bacani et al., 2006). 
 
8.2. The CDH1 gene and Sporadic Gastric Cancer (SGC) 
 
Somatic alterations on the other hand have been implicated in the development of 
sporadic gastric cancer. The hot spot regions of these mutations are exons 7 to 10 of the 
E-cadherin gene, with exons 8 and 9 being the commonly mutated regions (Ascano et 
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al, 2001; Oliveira et al., 2009). However, they have also been detected in exons 2, 3, 5 
and 16. Approximately 31% of stomach cancers carry E-cadherin (CDH1) somatic gene 
mutations (Corso et al., 2013). The majority of these genetic changes have been 
identified as a second hit mechanism in familial gastric cancer, with the incidence of the 
second hit being 75% (Oliveira et al., 2009). 
 
Unlike germline mutations, only a few studies have investigated somatic mutations in 
gastric cancer (Becker et al., 1994; Becker et al., 1998; Ascano et al., 2001; Machado et 
al., 2001; Li et al., 2012). Becker and colleagues discovered mutations that resulted in 
the loss of cell-cell adhesion, in exons 8; 9 and 10. Furthermore, amino acid 
substitutions; aspartic to valine and valine to arpatic were identified in codons 370 and 
473 in exons 8 and 10, respectively. These amino acid substitutions resulted in the 
elimination of calcium binding sites hence a loss of function (Becker et al., 1994).   
 
Mutations were detected in exon 3 (129 bp deletion) which resulted in the substitution 
of histamine to tyrosine. In exon 4, 63 nucleotides and 20 amino acids were deleted. 
Further, amino acid substitutions; glutamic to glutamine and arginine to glutamine were 
identified in exons 10 and 12, respectively. These genetic changes were shown to have 
an association with the loss of protein function (Becker et al., 1998). In 2001, CDH1 
genetic mutations were identified in 7 of 25 diffuse type cases. In addition, novel 
mutations ag/AGT to cg/AGT; c insertion at 1208 and 5 bp insertion at 1216 g1849a) in 
intron 7, exon 9 and 12 were identified in 4 diffuse type cases. These mutations resulted 
in an aberrant protein expression (Ascano et al., 2001).   
A study by Machado and colleagues identified 56.3% of somatic changes in 16 diffuse 
gastric cancers. Five of these mutations produced single amino acid substitutions 
(1742T>C; 1108G>C; 1436A>G; 1204G>A; 1000G>C). Furthermore, deletions, 
1027delC and 521del10 + 1del16 were also identified. Loss of protein expression was 
seen in all the nine patients (Machado et al., 2001). 
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8.3. CDH1 Large genomic alterations and gastric cancer 
 
Gastric adenocarcinoma can also arise as a result of large genomic changes (Oliveira et 
al., 2009; Pinheiro et al., 2010; Yamada et al., 2011). These genomic changes are 
commonly identified in populations with low prevalence of stomach cancer amongst 
CDH1 germline negative patients.  Oliveira et al., (2009) detected 6.5% large genomic 
deletions out of 93 patients. These deletions included Del exon 1-2(193593 bp); Del 
exon 1-2(5671 bp); Del 5'-UTR-exon 1(150 bp); Del exon 14-16(8078 bp) and Del exon 
16(828 bp) (Oliveira et al., 2009). Protein expression was not determined, however, it is 
believed that these genomic deletions are the cause of gastric cancer in patients negative 
for CDH1 germline mutations. 
 
Pinheiro et al., (2010) also discovered two large genomic deletions, 193.593 bp and 150 
bp in positions IVS2+57.595 and TSS, respectively (Pinheiro et al., 2010). Other 
deletions were identified by Yamada et al., (2011) and these involved a heterozygous 
c.1212del and a c.1212C deletion in exon 9. The c.1212C mutation produced a 
premature protein (p.Asn405Ile-fxX12) in codon 415. In addition, a c.164-? _387+?del 
deleted exon 3 and led to a truncated protein p.Val55GlyfsX38. All alterations damaged 
cell-cell attachment by disrupting the extracellular and cytoplasmic domains (Yamada et 
al., 2011).       
 
8.4. Microsatellite instability in gastric cancer 
 
Microsatellites are short tandem repeats (STRs) in a gene. These repeat sequences 
accumulate mutations due to polymerase slippage (Ottini et al., 2004). The genetic 
changes are referred to as microsatellite instability (MSI) and play a pivotal role in 
gastric cancer development (Shokal and Sharma, 2012). Five microsatellite markers 
(BAT25, BAT26, D5S346, D2S123 and D17S250) are commonly utilised to detect 
microsatellite status in gastric cancer. The microsatellites are considered microsatellite 
instability-high (MSI-H) when there is instability in two or more markers. On the other 
hand, microsatellites are microsatellite instability-low (MSI-L) if only one marker is 
unstable. They are microsatellite stable if there is no instability at any marker (An et al.,  
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2011). MSI is seen in 15 to 30% cases of stomach cancer and is commonly identified in 
intestinal tumours in the antrum, amongst the elderly people (Pedrazzani et al., 2009). 
 
Studies have also reported MSI as a contributing factor in gastric carcinogenesis (Oki et 
al., 2009; Jeong et al., 2010). A study investigating microsatellite instability in 240 
gastric cancer patients identified MSI-H, MSI-L and MSS in 22, 25 and 193 individuals, 
respectively. MSI-L and MSS were associated with older patients, tumour site (antrum) 
and lymph vessel involvement. No association was observed between MSI-H and 
clinicopathologic characteristic (Oki et al., 2009). Jeong showed that MSI was 10.2% in 
a study which included 49 patients. The MSI positive tumours were all intestinal types 
(Jeong et al., 2010). Research conducted in 2009 in 250 patients showed that MSI 
occurred in 25.2% of the study cohort. Of these MSI positive cases, there were 41.8% 
intestinal types (Pedrazzani et al., 2012).   
 
Other studies have also investigated the impact of microsatellites in gastric cancer 
(Perez et al., 2004; Liu et al., 2005; Beghelli et al., 2006). One study involved a total of 
510 patients and detected MSI in 83 of the cases. The instability was commonly 
observed in older female patients (33%) in the intestinal type. It was seen less 
frequently in advanced cancers and those with a lymph node involvement (Beghelli et 
al., 2006). Liu and colleagues investigated 36 cases in which MSI was identified in 21 
(58.3%) of these cases. Further, MSI-H and MSI-L were seen in 7 and 14 of the 
tumours, respectively. There was a correlation between the MSI data and the 
clinicopathologic features. MSI-H/MSI-L was correlated with stage II and the location 
of the tumour in the distal stomach (Liu et al., 2005).    
 
Perez et al., (2004), analysed 24 sporadic cases in their study and identified 5 MSI 
positive patients of which 3 were of the intestinal type and 2 of the diffuse type. These 
early stage tumours were located in the proximal stomach and had no lymph node 
involvement (Perez et al., 2004).   
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8.5. CDH1 Polymorphisms in gastric cancer  
 
Single Nucleotide Polymorphims (SNPs) are single base pair genetic changes in a DNA 
sequence (Medina-Franco et al., 2007). They can be used as genetic markers to ascertain 
the association between certain genes and the risk of cancer growth. Different studies 
have investigated these genetic markers in stomach carcinogenesis (Machado et al., 
2001; Zhan et al., 2012). Various polymorphisms of the E-cadherin gene increase the 
risk of this malignancy. In one study, the effect of four polymorphisms such as rs13689, 
rs1801552, rs16260 and rs17690554 was investigated on the CDH1 gene. There was an 
association between two SNPs (rs16260 and rs17690554) with the risk of developing 
diffuse gastric cancer in 30% and 22% of 57 patients, respectively (Zhan et al., 2012). 
Research by Al-Moundhri and colleagues investigating 4 polymorphisms in a study that 
involved 192 patients showed that there was an association between the polymorphism 
and the risk of developing gastric cancer in 60% individuals.  
 
One of these SNPs (-160 C>A) had an association with an enhanced risk of developing 
the cancer in 60% of the patients (Al-Moundhri et al., 2010). Another study investigated 
12 SNPs (rs16260, rs1559366, rs10431923, rs7188750, rs1801552, rs33965115, 
rs1801026, rs13689, rs1477407, rs12935840, rs8062856, rs2232228). Amongst these 
polymorphisms, rs1801026 and rs13689 had an association with the development of the 
cancer. However, this association with rs13689 was found not to be statistically 
significant (Jacobs et al., 2011).   
 
A study by Zhang et al., (2008), involved 96 SGC patients and determined the effect of -
347delA, -160C>A, -73A>C, +178T>C and +234 13N ins>del SNPs in the CDH1 gene 
promoter area. Amongst these variants; -347delA, +178T>C and +234 13N ins>del 
cooperatively enhanced the risk of the tumour in 65.8% SGC individuals (Zhang et al., 
2008). Other variants namely; rs10673765, rs9932686, rs1125557, rs9282650 and 
rs9931853 were also investigated amongst 134 DGC patients by Nasri et al., (2008). 
The rs1125557 (also referred to as 163+37235G>A) was seen in 56.7% of the patients 
and thus increased the risk of the disease (Nasri et al., 2008). Medina-Franco and 
colleagues identified an association between the -160 C/A SNP and 16 of 39 DGC 
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patients (Medina-Franco et al., 2007). Polymorphisms are therefore associated with the 
risk of developing stomach cancer.  
 
9. Aims and Objectives 
 
The primary aim of this study was to determine the prevalence of E-cadherin (CDH1) 
genetic mutations in gastric cancer patients seen in the Western Cape and to correlate 
these findings with the demographic/clinicopathologic data. The mutational data was 
obtained using PCR and sequencing molecular techniques.  The objectives of this study 
were to: 
 Sequence the CDH1 gene in a cohort of gastric cancers. 
 Analyse CDH1 mutations in the gastric cancer patients. 
 Correlate the molecular and demographic/clinicopathologic data. 
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CHAPTER 2 
Materials and Methods 
 
2.1. Ethical Approval 
 
Ethics approval for the study was obtained from the Human Research Ethics 
Committee, Faculty of Health Sciences (HREC REF: 504/2009), at University of Cape 
Town. 
 
2.2. Case Selection 
 
One hundred and two gastric tumour and their corresponding normal tissue samples 
were obtained from the archives of the Division of Anatomical Pathology, University of 
Cape Town/NHLS. A statistician was consulted to assist with determining the 
appropriate sample size to include in the study. The number of cases selected was based 
on the worldwide prevalence or proportion of the E-cadherin gene mutations from 
literature reviewed. After staining the cases with haematoxylin and eosin (H & E), the 
slides were examined by a pathologist, Dr Michael Locketz, (Pathologist and 
Collaborator) from the Division of Anatomical Pathology, NHLS/UCT. The normal and 
tumour areas were demarcated on the slide and only cases presenting with more than 
80% tumour were included in this study.  
 
2.3. Pathologic Case Reports 
 
The case reports were reviewed from the laboratory information system and staged 
according to the TNM system, 2002 AJCC Cancer staging (Manual, 6th Ed, New York, 
2002, Springer), see Appendix D. In addition, information related to age, gender and H. 
pylori status was also retrieved from the reports. Furthermore, the patients’ previous 
gastric biopsy case reports were reviewed to ascertain whether H. pylori were present or 
absent. All the biopsy specimens were examined for the presence of H. pylori using a 
modified Giemsa stain.  
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2.3. Histology 
 
The corresponding archived tissue blocks for the 102 cases had been previously fixed in 
10% buffered formaldehyde and processed overnight in an automatic tissue processor 
(Tissue Tek VIP, Sakura Finetek, Torrance, CA). They were then embedded into wax 
blocks using the Tissue Tek embedding machine (Sakura Finetek, Torrance, CA, USA). 
These wax blocks were cut at 3µm and 6µm with a rotary microtome (Accu-Cut SRM 
200 Rotary Microtome, Serial No: 1429-0925). Sterile conditions were adhered to at all 
times. The Accu-Edge Low-Profile Blades were wiped with alcohol and gloves were 
worn during sectioning. The tissue sections were then picked up on glass slides and heat 
fixed on a hotplate at 60°C for 10 minutes. The 3µm sections were stained with 
haematoxylin and eosin whilst the three 6µm sections were used for the molecular 
studies of this project. 
 
2.4. Haematoxylin and Eosin (H & E) Staining 
 
The 3µm gastric tissue sections were dewaxed in xylene, passed through a series of 
absolute alcohol and finally washed in running tap water. Mayers haematoxylin was 
used to stain the slides for 6 minutes. The slides were rinsed in tap water and the nuclei 
blued with ammoniated water. The slides were then washed, and a 1% phloxine/eosin 
was used to stain the cytoplasm and surrounding tissue for 5 minutes. The cytoplasm 
and surrounding tissue stained various shades of pink. Finally, the slides were washed 
thoroughly in water, dehydrated in alcohol and cleared in xylene. Entellan was used to 
mount the slides onto cover slips. 
 
2.5. DNA Extraction 
 
The three 6µm sections were dewaxed in xylene, cleared in alcohol, thoroughly washed 
in running tap water, and left to air dry. After the unstained slides were dried, they were 
superimposed onto the H & E slides previously marked by a pathologist. The normal 
and tumour regions were demarcated on the unstained slides. The three sections of 
normal and tumour tissues were scrap ed and transferred into autoclaved 1.5ml 
Eppendorf tubes which were labelled accordingly. DNA isolation was performed 
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utilizing the QIAamp®DNA FFPE Tissue extraction kit (Whitehead Scientific) 
according to the manufacturer's protocol. This consisted of heating the samples in the 
Eppendorf tubes with 20µl PK and 180µl ATL lysis buffer at 56ºC. A heat block was 
used to deactivate the PK at 90 ºC for 1 hour. The tubes were then centrifuged and 
200µl of AL (lysis) buffer together with 200µl of absolute ethanol was added to this and 
mixed by vortexing. After centrifuging, the entire lysate was transferred to a 
QIAampMinElute column (in a 2ml collection tube). The collection tube with the flow 
through was replaced with a new one and 500µl of AW1 (wash) buffer was added to the 
column. After centrifuging the collection tube with the flow through was discarded and 
replaced. 500µl of AW2 (wash) buffer was added to the column and centrifuged. The 
column with the flow through was once again discarded and replaced with a new one. 
The membrane of the column was allowed to dry completely by centrifuging. The 
collection tube was discarded and replaced with a 1.5ml microcentrifuge tube. 50µl of 
ATE (eluting) buffer was applied to the membrane of the QIAampMinElute column 
which was once again centrifuged. The flow through was collected and stored at -20  C 
for further tests. The end product being 50µl of purified DNA. 
 
2.6. DNA quantification 
 
The DNA samples were quantified using a Nanodrop instrument (Thermo Scientific, 
Wellington, DE 19810 USA) prior to insulin PCR. This instrument allows the 
quantification of samples such as proteins and nucleic acids (DNA and RNA). A 2µl 
volume of the DNA samples was used for quantification. 
 
2.7. Insulin PCR 
 
Insulin PCR was performed to verify the quality of DNA extracted from FFPE tissues. 
The insulin gene was amplified using the exon 2 region with exon-specific primers: 5'-
AGG GGC AGC AAT GGG CGG TTG-3' (reverse) and 5'-ACC CAG ATC ACT GTC 
CTT CTG CC-3' (forward). The PCR product size for these primers was 236 base pairs 
(bp). A 25µl PCR reaction was carried out containing 5μl of template DNA, 5pmol of 
each primer, 10mM dNTPs, 10x PCR buffer, and 5u/μlTaq DNA polymerase. The PCR 
conditions were as follows: 
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a). Initial Denaturation 1 cycle: 94  C for 5 minutes 
b). 30 cycles: 94  C for 1 minute 
                    : 64  C for 1 minute 
                    : 72  C for 2 minute 
c). Final Extension cycle: 72  C for 10 minutes 
 
2.8. Gel Electrophoresis 
Following insulin PCR, the amplicons were separated on 1.5% Agarose/Ethidium 
Bromide gel in 1x TBE buffer and run at 100 V for 45 minutes and then visualized 
under UV-transillumination using the SynGene Image Acquisition Software (SynGene 
Version 7.05.02). A 100 bp molecular weight marker (Hyperladder IV) purchased from 
BIOLINE was used to determine the DNA product size. 
 
2.9. Primer Design 
 
All studies thus far investigating sequence analysis of the E-cadherin (CDH1) gene in 
gastric cancer, showed that the main hotspots are located on exons 8 and 9 (Berx, et al., 
1995; Oliveira et al., 2009). This study also focused on investigating these exons since 
to date there is no published data on these investigations in South Africa. The primer 
sets were therefore designed for exons 8 and 9 using bioinformatics software namely, 
Primer3 and Oligoanalyzer. The Oligoanalyzer software was utilized to analyse primer 
properties such as hairpins, self and cross dimers. These are primer secondary structures 
produced as a result of self-complementarity within the primers. Since these secondary 
structures may interfere with amplification, they should be avoided during primer 
design. The primers (Table 1) were synthesised in the Department of Molecular Cell 
Biology at University of Cape Town (UCT). The PCR product size for exon 8 and 9 
primers was 188 bp and 230 bp (Table 1), respectively. 
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Table 1: PCR Primer sequences for exons 8 and 9. 
Region                       Forward                                                            Reverse                                       
Exon 8        5’-ACTTGGTTGTGTCGATCTCT-3’       5’-CTTTGGAAACCCTCTAAGGA-3’ 
Exon 9        5’-TGACACATCTCTTTGCTCTG-3’       5’-CATCTTGCCAGGTACCATAC-3’          
 
2.9.1. Exon 8 PCR 
 
The PCR was performed in a final reaction volume of 50µl consisting of 3.5µl of 
template DNA (120ng); 10µM of each primer; 5u/µl of My Taq DNA polymerase and 
5x My Taq PCR reaction buffer containing 5mM dNTPs and 15mM MgCl2. Positive 
(50ng/µl high quality genomic DNA from a human blood sample) and negative controls 
(sterile water) were included in the reaction. These reagents were purchased from 
BIOLINE. The PCR was performed under the following conditions: 
 
a). Initial Denaturation 1 cycle: 94  C for 5 minutes 
b). 30 cycles: 94  C for 1 minute 
                    : 48  C for 1 minute 
                    : 72  C for 1 minute 
c). Final Elongation cycle: 72  C for 7 minutes 
 
2.9.2. Exon 9 PCR 
 
The PCR was performed in a final reaction volume of 50µl consisting of 3.5µl of 
template DNA (120ng); 10µM of each primer; 5u/µl of My Taq DNA polymerase and 
5x My Taq PCR reaction buffer containing 5mM dNTPs and 15mM MgCl2. Positive 
(50ng/µl genomic DNA sample) and negative controls (sterile water) were included in 
the reaction. These reagents were purchased from BIOLINE. The PCR was performed 
under the following conditions: 
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a). Initial Denaturation 1 cycle: 94  C for 5 minutes 
b). 30 cycles: 94  C for 1 minute 
                    : 50  C for 1 minute 
                    : 72  C for 1 minute).  
Final Elongation cycle: 72  C for 7 minutes 
 
2.10. Gel Electrophoresis 
 
The PCR products were run on a 1.5% Agarose/Ethedium Bromide gel in 1x TBE buffer 
at 100 V for 45 minutes to determine the size and also verify the presence of DNA. 
They were visualized under UV-transillumination using the SynGene Image Acquisition 
Software (SynGene Version 7.05.02). A 100 bp molecular weight marker from 
BIOLINE was used to determine the size of PCR products. 
 
2.13. Nested PCR 
 
The nested PCR was carried out to improve DNA amplification since the standard 
sequencing PCR was unsuccessful in the majority of the samples. The unsuccessful 
PCR may have been due to the DNA quality affected by formalin fixing and paraffin 
embedding, when the tissue blocks were generated. Another factor that contributes to 
DNA damage is the storage time; the DNA from FFPE tissues becomes fragmented as 
the tissues get older. The latter, therefore makes it difficult to amplify DNA extracted 
from FFPE tissues, hence the DNA samples were subjected to further optimization 
using the antigen retrieval process. Since the nested PCR involves two sets of primers 
where the product from the first reaction is used as a template for the second reaction; 
new sets of primers which generate a bigger product size (397 bp and 484 bp for exon 8 
and 9, respectively) were used. 
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2.13.1. Exon 8 nested PCR  
 
Two sets of primers (Table 2 and Table 3) were used to amplify each exon. To amplify 
exon 8, the primer set I was used. The PCR was performed in a final reaction volume of 
25µl consisting of 3.5µl of template DNA (120ng); 10µM of each primer; 5u/µl of My 
Taq DNA polymerase and 5x My Taq PCR reaction buffer containing 5mM dNTPs and 
15mM MgCl2. Positive (50ng/µl genomic DNA sample) and negative controls (sterile 
water) were also included in the reaction. The PCR products from this reaction were 
used as DNA templates for the second reaction using the primer set II. The PCR product 
size for exon 8 was 397 bp. The PCR was performed under the following conditions: 
 
a). Initial Denaturation 1 cycle: 94  C for 5 minutes 
b). 30 cycles: 94  C for 1 minute 
                    : 50  C for 1 minute 
                    : 72  C for 1 minute 
c). Final Elongation cycle: 72  C for 7 minutes 
 
2.13.2. Exon 9 nested PCR 
 
Exon 9 was amplified in a final volume of 25µl consisting of 3.5µl of DNA (120ng); 
10µM of each primer (primer set I); 10X PCR reaction buffer without MgCl2; 5u/µl Taq 
DNA polymerase; 10mM of dNTPs and 5mM of MgCl2. Positive (50ng/µl genomic 
DNA sample) and negative controls (distilled water) were also included in the reaction. 
The PCR products from this reaction were used as DNA templates for the second 
reaction using the primer set II. The PCR product size for exon 9 was 484 bp. The PCR 
was performed under the following conditions: 
 
a). Initial Denaturation 1 cycle: 94  C for 5 minutes 
b). 30 cycles: 94  C for 1 minute 
                    : 53  C for 1 minute 
                    : 72  C for 1 minute 
c). Final Elongation cycle: 72  C for 7 minutes 
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Table 2: PCR Primer sequences for exon 8. 
Primer set                    Forward                                                                  Reverse                                       
I             5’-TGTCAGTTAATACAGTGATGGT-3’    5’-ACTAAAAGACAACTGCCATCT-3’ 
II           5’-AGCTTTGCATCTAAGCTTGT-3’          5’-TCTGGAGAGAGTTTTCAAAGA-3’ 
 
Table 3: PCR Primer sequences for exon 9 
Primer set                    Forward                                                                  Reverse                                       
I            5’-TTGTCACATCTTCTCCTTGA-3’           5’-TGCCTGGCTAATTTTTGTAT-3’ 
II           5’-TGTCAGTTAATACAGTGATGGT-3’     5’-ACTAAAAGACAACTGCCATCT-3’ 
 
2.14. DNA Sequencing of PCR products 
 
The PCR products were diluted prior to sequencing. A volume of 60µl together with 
10µM of each primer (forward and reverse) was sent to Macrogene, a company based in 
South Korea. This company offers sequence analysis of plasmid and PCR products 
using a high throughput Applied Biosystems 3730XL sequencer. The PCR primers with 
188 bp and 230 bp product size were used for the sequencing reaction of exon 8 and 9, 
respectively. The DNA products were amplified using a BigDye Terminator V1.1/3.1 kit 
(Applied Biosystems, Forster City, CA 94404, U.S.A.). Bioinformatics tools; ClustalW 
and BioEdit were used to analyse CDH1 genetic mutations. 
 
2.15. Statistical A alysis 
 
The demographic/clinicopathologic data was analysed using Stata 11.  
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CHAPTER 3 
3. Results 
 
3.1. Demographic and clinicopathologic characteristics of study participants 
 
A total of 102 gastric cancer cases were enrolled in the study (Appendix C). The mean 
age of these participants was 57 years (range: 18-84 years). Ninety six patients had their 
gastric cancers classified as intestinal (n = 38), diffuse (n = 53) and mixed (n = 5), 
according to the Lauren classification system. Two patients were classified as mucinous 
adenocarcinoma and 4 were not classified. Our study consisted of 48 male patients and 
51 female patients and gender was not stated in 3 cases. The tumours were grouped into 
different stages 0 (3 patients); IA (6 patients); IB (13 patients); II (24 patients); IIA (3 
patients); III (2 patients); IIIA (19 patients); IIIB (11 patients); IIIC (1 patient) and stage 
IV (5 patients). Twelve of the patients were not classified for stage. Further, they were 
categorized into grade 1 (2 patients); grade 2 (29 patients); grade 3 (32 patients) and 
grade 4 (30 patients) and 7 individuals were not classified for grade. There were 54 
patients who had lymph node metastasis; 25 patients were negative and 23 were not 
reported for lymph node metastasis. For H. Pylori infection, only 24 patients were H. 
Pylori positive; 76 were negative and the infection was not reported in 2 individuals 
(Table 4). 
 
3.2. Descriptive statistics of demographic/clinicopathologic data   
 
The patients were categorised into different age groups (Figure 5), <50 years, 50-69 
years and >70 years. 
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Figure 5: The distribution of different age groups in gastric cancer patients. 
 
 
 
  
Figure 6: The relation between gender and the histologic types of gastric cancer is 
indicated. The diffuse type is commonly seen amongst female patients (61.11%) while 
the intestinal type is more frequent amongst the male patients (62.15%). 
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Figure 7: The distribution of histological types in gastric cancer patients. 
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Table 4: The demographic/clinicopathologic characteristics of the (study cohort) 102 
cases. 
 
 
 
 
Clinicopathologic feature No. of cases with valid entry/102 
Age (yrs) 98 
Sex Ratio (Male:Female) 48:51 
Gender not stated 2 
Stage  
0 3 
IA 6 
IB 13 
II 24 
IIA 3 
III 2 
IIIA 19 
IIIB 11 
IIIC 1 
IV 5 
No stage assigned 12 
Grade  
1 2 
2 29 
3 32 
4 30 
Not graded 7 
Lymph node metastases  
No 25 
Yes 54 
Lymph node metastases not assigned 23 
H.pylori  
No 76 
Yes 24 
H.pylori status not assigned 2 
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3.2. Microscopic examination of intestinal and diffuse gastric adenocarcinoma 
 
All the gastric cancer cases (102) selected for this study were reviewed and examined 
by a pathologist (Dr M Locketz) and categorized as the diffuse and intestinal histologic 
types.  
 
 
Figure 8: A diagrammatic representation of the intestinal (A) and diffuse (B) types of 
gastric cancer. The intestinal type is characterized by glands and the diffuse type by 
single line dis-cohesive cells. 
  
3.3. Verification of DNA quality  
 
DNA was isolated from all the 102 samples and the exon 2 region of the insulin gene was 
amplified using PCR to verify the quality of the DNA. However, the insulin PCR was only 
successful in 44 samples. This was due to the DNA not being of optimal quality due to formalin 
fixing and paraffin embedding. A statistician was consulted and the Epicalc2000 software 
was used to determine the sample size. A sample size of 20 was deemed adequate for 
this study. A representative 1.5% agarose gel of DNA samples is shown (Figure 9). A 
successful DNA isolation of the samples was indicated by the presence of a 236 bp PCR 
product.  
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Figure 9:  Representation of a 1.5% agarose gel showing amplification of exon 2 of the 
insulin gene which produces a PCR (236 bp) product. Lanes 1 to 10 represent the DNA 
samples; lane 11 positive (+) and lane 12 negative control (-); M, a 100 bp ladder. 
 
3.4. E-cadherin (CDH1) gene amplification 
 
Exon 8 and 9 of the CDH1 gene were amplified. Of the 44 samples, only 26 (Table 5) 
could be amplified on exon 8 whilst only 2 could be amplified on exon 9. 
Representative 1.5% agarose gels of DNA samples are shown in Figure 10 and Figure 
11. A successful DNA amplification was indicated by the presence of PCR products of 
size 397 bp and 484 bp for exon 8 and 9, respectively. 
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 Figure 10: Representation of a 1.5% agarose gel showing amplification of exon 8 of 
the CDH1 gene which produces a PCR (397 bp) product. Lanes 1 to 11 represent the 
DNA samples; lane 12 positive (+) and lane 13 negative controls (-); M, a 100 bp 
ladder. 
 
 
 
 
Figure 11: Representation of a 1.5% agarose gel showing amplification of exon 9 of the 
CDH1 gene which produces a PCR (397 bp) product. Lanes 1 to 11 represent the DNA 
samples; lane 12 positive (+) and lane 13 negative controls (-); M, a 100 bp ladder. 
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Table 5: The demographic and clinicopathologic features of the 26 cases. 
Patient 
ID Gender Age H.pylori Node Grade Stage Type  
T2 F 77 0 No     2 0 Intestinal 
T3 M 78 0 NR     4 IB Intestinal 
T7 M 54 1 NR     1 IA Intestinal 
T17 F 74 0 Yes    4 IIIA Diffuse 
T30 M 48 0 Yes   NR IIIB Diffuse 
T68 F 36 0 NR    4 III Diffuse 
T72 F 37 1 No   3 0 Diffuse 
T79 F 64 1 Yes   4 IV Diffuse 
T82 F 37 1 No   3 0 Diffuse 
T91 F 61 0 Yes   3 NR Diffuse 
T92 M 60 0 No   3 IIA Diffuse 
T95 F 42 1 No   3 IB Diffuse 
T16 M 84 1 No   2 NR Intestinal 
T81 M 64 0 Yes   3 IIIA Diffuse 
T11 F 38 0 Yes NR IIIA Diffuse 
T12 F 77 0 NR  3 IV Intestinal 
T13 M 60 0 No  2 NR Intestinal 
T18 M 60 0 No  2 IB Intestinal 
T31 F 70 0 Yes  2 IIB Intestinal 
T32 F 43 0 No  4 IB Diffuse 
T35 M 52 0 Yes  2 IIIB Intestinal 
T38 F NR 0 Yes  2 IIIA Intestinal 
T39 M 60 0 NR  3 1B Intestinal 
T42 M 46 0 Yes  4 IIIA Diffuse 
T67 F 52 0 No  4 II Diffuse 
T70 F 78 1 NR  4 II Diffuse 
Key: 
NR    Not Recorded  
0       H. pylori negative 
1       H. pylori positive        
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3.5. Sequence analysis 
 
After the amplification of exon 8 and 9 of the CDH1 gene, the PCR products were 
subjected to a sequencing reaction. The sequencing data of each patient was then 
analysed. 
 
 
Figure 12: A representative chromatogram of sample T68 showing sequencing data as 
obtained from Macrogene. 
 
 
Figure 13: A representative chromatogram of sample T79 showing sequencing data as 
obtained from Macrogene. 
A>G, 63 
A>T, 84 
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Table 6: Nucleotide changes in the exon 8 of the CDH1gene. 
Case numbers Nucleotide change Amino acid change Position 
T68 A>G                                                                                      No 63 
T79 A>T         No 84 
 
3.6. Immunohistochemistry 
 
Immunohistochemistry was performed in another study which was part of our 
comprehensive gastric research project conducted in the Division of Anatomical 
Pathology. The same gastric cancer cases were used. The E-cadherin 
immunohistochemical stains (Figure 14) for the two cases (T68 and T79) which 
presented with somatic mutations in this study were reviewed. The E-cadherin protein 
expression was analyzed by a pathologist (Dr Michael Locketz) for these two cases. 
 
Figure 14: The immunohistochemistry stains showing the E-cadherin protein expression 
(with DAB chromogen). Sample T68 (A) - showing membrane positivity.  Sample T79 
(B) - showing absence or loss of E-cadherin. 
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CHAPTER 4 
 
4. Discussion 
 
4.1. Clinicopathologic features of tumours from gastric cancer patients 
 
Gastric cancer is the fourth most frequent cancer having new cases estimated at 988,000 
and 736,000 deaths with the majority of cases occurring in underdeveloped populations 
(Globacan, 2008). This disease has been rated as the second leading cause of cancer 
death worldwide (Parkin. 2001; Buffart et al., 2011). However, incidence and death 
rates vary greatly amongst different populations. The highest incidences of this cancer 
are seen in Africa, Eastern Asia and South America. Stomach cancer is less frequent in 
more developed regions such as Europe, Australia, New Zealand and North America 
(Globacan, 2008). The disease has also been seen as an important health problem in 
different populations of South Africa (Kidd eta l., 1999; Chetty et al., 2002; Dube et al., 
2009). 
The study cohort included the analysis of 102 cases for the different clinicopathologic 
features (lymph node metastasis, Helicobacter pylori infection, tumour grade and stage) 
that are commonly seen in gastric cancer (Appendix C). Further, the patients presented 
with different histologic types, diffuse, intestinal, mixed (diffuse/intestinal) and 
mucinous adenocarcinoma (Appendix C). Of the 102 patients, the majority 52.94% (54 
patients) presented with lymph node metastasis, 25 patients (24.51%) did not have 
lymph node metastasis and 23 (21.56%) were not recorded for lymph node metastasis.  
The H.pylori infection is an important environmental factor in the pathogenesis of 
stomach adenocarcinoma. With respect to H. pylori infection, the majority of our 
patients (74.51%) were negative for the infection, only 23.53% had the infection. 
Further, the H. pylori status was not recorded in 2 (1.96%) cases. Although, H. pylori is 
the major contributing factor to the development of gastric cancer (Bartchewsky et al., 
2009), the frequency is low in our patient cohort. In addition, the clinical history of each 
patient was reviewed to check for the presence of H. pylori in previous biopsy reports. 
Only 2 of the 102 cases were positive for H.pylori infection.  
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With respect to the grade of the tumour, only 2% presented with grade 1 of the cancer. 
The frequency of grade 2 tumours was 28% and grade 3 tumours were seen in 31% of 
the cases. Grade 4 tumours were seen at a frequency of 30%. In line with our study, 
other studies have also shown that grade 3 and grade 4 tumours are commonly observed 
than grade 1 and 2 in gastric cancer patients (Suriano et al., 2003; Oliveira et al., 2009; 
Corso et al., 2013;). 
When gender was correlated with the histologic type (Figure 6), the intestinal type was 
more common in males (62.16%) than females (37.84%) and the diffuse type was more 
frequent in females (61.11%) than males (38.89%). These results are in line with those 
observed by Correa Hackenson et al., (2010); Piazuelo, (2011) and Corso et al., (2012). 
However, our results may be biased, because the cases were collected to balance the two 
histologic types.  When analysing the incidence of the cancer in different age groups 
(Figure 5), gastric cancer was seen at a frequency of 30.61% in patients younger than 50 
years. The incidence was also more frequent (47.96%) in patients between the ages of 
50 and 69.Additionally, the tumour was less common (21.43%) in the older age group 
(70 to 90 years). 
 
4.2. Sequence analysis of the CDH1 gene 
 
The CDH1 gene plays an important role in the pathogenesis of stomach cancer. Various 
studies have shown that this gene tends to accumulate both germline and somatic 
mutations in its coding sequence (Berx et al., 1998; Pharoah et al., 2001; Kaurah et al., 
2007; Oliveira et al., 2009). However, the number of studies related to somatic 
mutations is sparse. Different tissue samples such as blood, fresh frozen material, 
surgical specimens and FFPE tissues have been used to isolate nucleic acids (DNA or 
RNA) for molecular analysis. Our study used FFPE tissues as a source of DNA. We 
were able to successfully amplify only 44 of the 102 samples included in the study. Of 
the 44 cases which had good quality DNA (Figure 9), we managed to amplify only 26 
DNA samples for exon 8 of the CDH1 gene (Figure 10). With regards to exon 9 
however, only two samples were amplifiable (Figure 11). Further, these 2 samples 
produced faint DNA bands (low DNA concentration). It is possible that no sequencing 
data was obtained in these samples because of the quality of DNA. The quality of DNA 
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isolated from FFPE tissues could be the reason for unsuccessful amplification in exon 9. 
It is also well established that the formalin fixative forms cross links which compromise 
the DNA integrity (Thompson et al., 2005).  
 
Of the 26 cases analysed, CDH1 somatic mutations were seen in only 2 (7.6%) cases 
(Figure 12 and13) and 24 of our patients did not have nucleotide changes (Appendix A). 
These genetic mutations were single nucleotide changes that occurred at position 63 and 
84. The nucleotide changes were A>G and A>T in positions 63 and 84, respectively 
(Table 6). Our results are different from those of (Becker et al., 1994; Becker et al., 
1998; Ascano et al., 2001; Machado et al., 2001; Oliveira et al., 2009 and Corso et al., 
2013) that reported a higher frequency (28% to 75%) of CDH1 somatic mutations. 
Becker and colleagues identified CDH1 somatic mutations amongst diffuse gastric 
cancers, in 13 of 26 cases (50%). 
 
A study by Machado et al., (2001) showed a slightly higher prevalence of mutations in 
16 of 23(56.3%) cases analysed. Further, these mutations were observed only in the 
diffuse type (Machado et al., 2001). The differences in the frequencies of CDH1 somatic 
mutations could be due to a number of actors; the sample size and type of material 
used. Other investigations have used surgical specimens and fresh frozen tissues as a 
source of DNA, as opposed to our study which used FFPE tissues. DNA isolated from 
fresh frozen material has a better quality than that isolated from FFPE tissues. 
 
Since the aetiology of gastric adenocarcinoma has also been shown to be associated 
with other environmental and genetic factors (Crew and Neugut, 2006), it is possible 
that dietary factors have contributed to the pathogenesis of gastric cancer in the Western 
Cape. In high incidence regions like Japan, the development of this malignancy is 
mostly associated with poor food storage and diet. The Japanese usually utilize salt to 
preserve their food and therefore ingestion of salty foods and smoked fish was shown to 
contribute to gastric malignancy. Additionally, foods containing chemicals such as 
nitrite compounds, low fruit and vegetable uptake is also a risk factor of the disease 
(Brenner et al., 2009). Alcohol consumption and smoking have also been related to the 
pathogenesis of this malignancy (Inoue and Tsugane, 2005). Moreover, these factors 
might have played a role in the development of gastric cancer amongst the patients seen 
in the Western Cape, however this requires further investigations.  
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Other genetic factors like microsatellite instabilities, polymorphisms and germline 
mutations also contribute to the development of the disease. However, the prevalence of 
E-cadherin germline mutations ranges from 29% to 56% (Lynch et al., 2005; Bacani et 
al., 2006; Corso et al., 2012). Patients who do not present with germline mutations are 
further analysed for large genomic deletions. These deletions have therefore been 
implicated as another possible contributing factor towards the pathogenesis of gastric 
cancer amongst the E-cadherin germline negative individuals (Oliveira et al., 2009; 
Pinheiro et al., 2010; Yamada et al. 2011). It would therefore be interesting to explore 
the CDH1 large genomic deletions for future research. Another possible explanation is 
the presence of mutations in other genes namely, p53, STK11, MET, MLH1 and MLH2 
(Yamada et al., 2011). 
 
4.3. Association of CDH1 mutations with Clinicopath logic data and protein 
expression 
 
The 2 cases which had CDH1 mutations (T68 and T79) were both female patients and 
had the diffuse histologic type (Table 5). Case T68 was 36 years old and did not have 
H.pylori infection. Additionally, the tumour in this patient had spread to the serosa 
(stage III) of the stomach. On the other hand, case T79 was 64 years old and had the H. 
pylori infection. The tumour had spread to the lymph nodes and also the serosa of the 
stomach. These results may indicate that these mutations may be associated with an 
advanced stage of gastric cancer (stage III and IV), which is in line with the study by 
Corso et al., (2013). However, due to the low number of cases with mutations in our 
study, we cannot conclusively make any statistical correlations. It is interesting to note 
that other studies have shown similar results (Ascano et al., 2001; Machado et al., 2001; 
Corso et al., 2013). 
 
In sporadic gastric cancers, CDH1 gene somatic mutations are commonly associated 
with loss of E-cadherin protein expression (Ascano et al., 2001; Machado et al., 2001; 
Brooks-Wilson et al., 2004). In our study, E-cadherin protein expression in T79 (Figure 
14 B) was lost; patient T68 (Figure 14 A) on the other hand still expressed the E-
cadherin protein. Although other studies have shown an association between CDH1 
gene mutations and loss of E-cadherin protein expression, our study cannot make any 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
50 
 
definite conclusions since only two samples were analysed.  
 
In conclusion, our study showed that CDH1 genetic mutations were only observed in 2 
of the 26 samples (7.6%). The CDH1 genetic mutations are therefore not common in 
gastric cancer patients seen in the Western Cape. There was no correlation between the 
sequencing data and the clinicopathologic data. To our knowledge this is the first study 
that reports somatic mutations of the CDH1 gene in a cohort of gastric cancers using 
FFPE tissue in the South African setting.  
 
For future research, it would be interesting to use fresh tissue samples obtained from a 
prospective study, together with FFPE tissues as a source of DNA. Other genes (p53, 
STK11, MET, MLH1 and MLH2) may also be analysed for both germline and somatic 
mutations, to determine if they are possible contributing factors in gastric 
carcinogenesis. Further, large genomic deletions in patients negative for germline 
mutations may be interesting to investigate as they have also been shown as 
contributing factors. 
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    Appendices 
Appendix A: The chromatograms of the 26 cases  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T2 
T3 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T7 
T17 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T30 
A>G, 63 
T68 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T72 
A>T, 84 
T79 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T82 
T91 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T92 
T95 
ro W 100 110 120 110 
f T C A C T G ACA C CAAC G A T AAT G A T C TT CAA T CCC A CCA C GG TAATT C T . 
60 70 go '10 100 no \] m 
IC .-\CA.-I. CAG CAACA GC I GI G ATCACAG I CAC 10 ACAC CAAC G ..1.1 AA1 C C I CC G ATcn CAA I CC CAC CAC GC· IA. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T16 
T81 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T11 
T12 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T13 
T18 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T31 
T32 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T35 
T38 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T39 
T42 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T67 
T70 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
Appendix B: Preparation of reagents for Agarose Gel Electrophoresis 
 
A) Tris-borate/EDTA (TBE) (10X) 
 Tris base (54 g), boric acid (27.5 g) and EDTA (4.65 g) was dissolved in 
400ml of sterile water and then brought up to 500ml. 
 The solution was dissolved and stored at room temperature 
(approximately 25 C). 
     
B) Tris-borate/EDTA (TBE) (1X) 
 TBE (1X) was prepared using (10X) TBE in a final volume of 100ml 
 10ml of 10x TBE was mixed with 90ml of sterile water. 
 
C) Agarose gel (1.5%)  
 Agarose (1.8 g) was dissolved in 120 ml of 1X TBE. 
 The solution was heated up in a microwave until agarose granules 
completely dissolved. 
 The gel was allowed t  cool at room temperature, and then 10µl of 
ethidium bromide was added. 
 The mixture was poured into a casting tray containing a comb that was 
placed in one end of the tray. 
 The gel was allowed to set for 45 minutes at room temperature prior to 
use. 
 
 
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 
 
Appendix C: The demographic/clinicopathologic data of the 102 cases 
 
Patient 
ID Gender Age H.pylori Node Grade Stage Type 
 1 M 63 No No 2 IB Intestinal 
2 F 77 No No 2 0 Intestinal 
3 M 78 No NR 4 IB Intestinal 
 4 M 38 Yes No 3 IIA Diffuse 
 5 F 58 Yes Yes 4 IIA Diffuse 
 6 M 41 No Yes 2 II Intestinal 
 7 M 54 Yes NR 1 IA Intestinal 
 8 F 18 No NR 3 IIIA Mixed 
 9 M 53 No Yes 3 IIIB Diffuse 
 10 M 40 No No 4 IA Diffuse 
 11 F 38 No Yes NR IIIA Diffuse 
 12 F 77 No NR 3 IV Intestinal 
 13 M 60 No No 2 NR Intestinal 
 14 M 54 Yes Yes 3 II Intestinal 
 15 F 51 Yes No 2 IIIA Intestinal 
 16 M 84 Yes No 2 NR Intestinal 
 17 F 74 No Yes 4 IIIA Diffuse 
 18 M 60 No No 2 IB Intestinal 
 19 F 59 Yes Yes 4 II Intestinal 
 20 M 59 No NR 2 IB Intestinal 
 21 M 69 No No 2 IA Intestinal 
 22 F 50 Yes Yes 3 II Intestinal 
 23 M 44 No Yes 4 IIIB Diffuse 
 24 F 64 Yes Yes 3 IIIA NR 
 25 M 53 Yes Yes 2 IIIB Intestinal 
 26 F 43 No Yes 2 NR Mixed 
 27 M 78 No Yes 2 II Intestinal 
 28 M 36 No No 3 NR Diffuse 
 29 M 79 No No 3 II NR 
 30 M 48 No Yes NR IIIB Diffuse 
 31 F 70 No Yes 2 IIIB Intestinal 
 32 F 43 No No 4 IB Diffuse 
 33 M 46 No NR 3 II Mixed 
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Patient 
ID 
Gender Age H.pylori Node Grade Stage Type 
35 M 52 No Yes 2 IIIB Intestinal 
 36 M 49 No Yes 1 IV Intestinal 
 37 F 41 No Yes 3 NR Intestinal 
 38 F NR No Yes 2 IIIA Intestinal 
 39 M 60 No NR 3 IB Intestinal 
 41 F 72 No Yes 3 IIIA Intestinal 
 42 M 46 No Yes 4 IIIA Diffuse 
 43 F 54 No Yes 3 IIIA Diffuse 
 44 F 72 No Yes 2 1b Intestinal 
 45 M 81 No NR 2 1b Intestinal 
 46 F NR No NR 2 II Intestinal 
 47 M 82 No Yes 2 II Intestinal 
 48 M 36 No NR NR IV Diffuse 
 49 F 46 No Yes NR IIIA Mixed 
 50 M 66 Yes Yes 3 II Intestinal 
 51 M 43 No Yes 2 II Intestinal 
 52 M 72 No Yes 2 IV Intestinal 
 53 M 44 No Yes 4 IIIB Diffuse 
 54 F 64 Yes NR 2 IIIA Intestinal 
 55 M 69 No Yes 2 II Intestinal 
 56 F 73 No Yes 2 II Mucinous 
 57 M 52 No Yes 2 IB Intestinal 
 58 M 57 Yes No 3 NR Mixed 
 59 M 61 No NR 3 IA Diffuse 
 60 F 76 No Yes 2 IB Intestinal 
 61 F 73 No Yes 4 II Diffuse 
 62 M 57 No No 3 II Intestinal 
 63 F 54 No Yes NR IA Diffuse 
 64 F 58 Yes Yes 2 II Intestinal 
 65 F 53 No Yes NR IIIA Diffuse 
 66 M 42 No NR 2 IIIA Mucinous 
 67 F 52 No No 4 II Diffuse 
 68 F 36 No NR 4 III Diffuse 
 69 F 33 No No 3 IB Diffuse 
 70 F 78 Yes NR 4 II Diffuse 
 71 M 60 No No 3 IB Diffuse 
 72 F 37 Yes No 3 0 Diffuse 
 73 F 62 No Yes 4 II Diffuse 
 74 M 63 No NR 4 IIIA Diffuse 
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Patient 
ID 
Gender Age H.pylori Node Grade Stage Type 
76 F 41 No Yes 4 II Diffuse 
 77 F 62 Yes Yes 4 IIIA Diffuse 
 78 F 73 No Yes 4 IIIB Diffuse 
 79 F 64 Yes Yes  4 IV Diffuse 
 81 M 64 No Yes 3 IIIA Diffuse  
82 M 32 No No 4 III Diffuse 
 83 F 60 Yes NR 4 II Diffuse 
 84 M 55 No Yes 4 IIIB Diffuse 
 85 F 65 No Yes 4 NR Diffuse 
 86 F 44 No NR 4 II Diffuse 
 87 M 44 No No 3 IA Diffuse 
88 F 75 Yes Yes NR IIIA Diffuse 
 89 F 69 Yes Yes 3 NR Diffuse 
 90 NR NR NR NR 3 NR NR 
 91 F 61 No Yes 3 NR Diffuse 
 92 M 60 No No 3 IIA Diffuse 
 93 F 67 No No 4 IIIA Diffuse 
94 M 40 No No 3 NR Diffuse 
 95 F 42 Yes No 3 IB Diffuse 
 96 M 57 No No NR NR Diffuse 
97 M 44 No Yes 4 IV Diffuse 
 98 M 82 Yes No 4 0 Diffuse 
99 NR NR NR NR NR NR NR 
 100 M 56 Yes Yes 3 NR Diffuse 
 101 F 58 No Yes 3 IIIC Diffuse 
 102 F 54 No Yes 3 IIIA Diffuse 
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Appendix D: Staging 
 
Stomach 
Primary Tumour (T) 
TX     Primary tumour cannot be assessed 
TO     No evidence of primary tumour 
Tis     Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria 
T1     Tumour invades lamina propria or submucosa 
T2     Tumour invades muscularis propria or subseroa 
T2a    Tumour invades muscularis propria 
T2b   Tumour invades subserosa 
T3  Tumour invades serosa (visceral peritoneum) without invasion of adjacent 
structures 
T4     Tumour invades adjacent structures 
*Note: A tumour may penetrate the muscularis propria with extension into the 
gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without 
perforation of the visceral peritoneum covering these structures. In this case, the tumour 
is classified T2. If there is perforation of the visceral peritoneum covering the gastric 
ligaments or the omentum, the tumour should be called T3. 
**Note: The adjacent structures of the stomach include the spleen, transverse colon, 
liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine and 
retroperitoneum. 
***Note: Intramural extension to the duodenum or esophagus is classified by the depth 
of the greatest invasion in any of these sites, including the stomach.  
Regional lymph nodes (N) 
NX   Regional lymph node(s) cannot be assessed 
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NO   No regional lymph node metastasis* 
N1   Metastasis in 1 to 6 regional lymph nodes 
N2   Metastasis in 7 to 15 regional lymph nodes 
N3   Metastasis in more than 15 regional lymph nodes 
*Note: A designation of pNO should be used if all examined lymph nodes are negative, 
regardless of the total number removed and examined. 
 
Distant metastasis (M) 
MX   Distant metastasis cannot be assessed 
MO   No distant metastasis 
M1   Distant metastasis 
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Stage grouping 
Stage    
    
Stage 0 pTis N0 M0 
Stage IA pT1 N0 M0 
Stage IB pT1 N1 M0 
 pT2a/b N1 M0 
Stage II pT1 N2 M0 
 pT2a/b 
pT3 
N1 
N0 
M0 
M0 
Stage IIIA pT2a/b N2 M0 
 pT3 N1 M0 
 
Stage IIIB       
Stage IV                           
pT4 
pT3 
pT4 
pT1-3 
Any pT 
 
N0 
N2 
N1-3 
N3 
Any N 
M0 
M0 
M0 
M0 
M1 
 
    
 
 
 
   
 
 
 
  
 
 
 
